

References

R-95

1. Abbas M and Kalia S. Trends in non-melanoma skin cancer (basal cell carcinoma and squamous cell carcinoma) in Canada: a descriptive analysis of available data. *J Cutan Med Surg.* 2016;20(2):166-75.
2. Agrawal S, Kane III JM, Guadagnolo BA, et al. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. *Cancer.* 2009;115(24):5836-5844.
3. Alam M, Nanda S, Mittal BB, et al. The use of brachytherapy in the treatment of nonmelanoma skin cancer: a review. *J Am Acad Dermatol.* 2011;65(2):377-388.
4. American Cancer Society: Skin cancer: Basal and Squamous Cell Skin Cancer.
5. Bhatnagar A. Clinical outcomes and patient-reported outcomes following electronic brachytherapy for the treatment of non-melanoma skin cancer. *J Radiat Oncol Biol Phys.* 2016;96(2 Suppl):E713.
6. Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. *Lancet Oncol.* 2012;13(6):589-597.
7. Chang DT, Amdur RJ, Morris CG, et al. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. *Int J Radiat Oncol Biol Phys.* 2006;66(4):1051-1055.
8. Eggermont AM, Chiarion-Sileni V, Grob, JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. *Lancet Oncol.* 2015;16(5):522-30.
9. Guadagnolo BA, Prieto V, Weber R, et al. The role of adjuvant radiotherapy in the local management of desmoplastic melanoma. *Cancer.* 2014;120(9):1361-1368.
10. Lee RJ, Gibbs JF, Proulx GM, et al. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. *Int J Radiat Oncol Biol Phys.* 2000;46(2):467-474.
11. Olivier KR, Schild SE, Morris CG, et al. A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. *Cancer.* 2007;110(8):1791-1795.
12. Mendenhall WM, Mancuso AA, Kiorwan JM et al. Skin: principles and practice of radiation oncology in Halperin EC, Wazer DE, Perez CA, and Brady LW, ed. *Perez and Brady's Principles and Practice of Radiation Oncology.* 6th Edition. Philadelphia, PA:Lippincott Williams & Wilkins, a Wolters Kluwer business, 2013:626-637.
13. Miller AJ and Mihm MC. Melanoma. *NEJM.* 2006;355(1):51-65.
14. National Comprehensive Cancer Network NCCN Radiation Therapy Compendium™.

15. National Comprehensive Cancer Network (NCCN) Guidelines. Version 1. 2018 – September 18, 2017. Basal Cell Skin Cancer.
16. National Comprehensive Cancer Network (NCCN) Guidelines. Version 2. 2018 – October 5, 2017. Squamous Cell Skin Cancer.
17. National Comprehensive Cancer Network (NCCN) Guidelines. Version -2. 2018 – January 19, 2018. Melanoma.
18. Sause WT, Cooper JS, Rush S, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. *Int J Radiat Oncol Biol Phys*. 1991;20(3):429-432.
19. Seegenschmeidt MH, Tepper JE, Gunderson LI. Benign Diseases (chapter 65) in: Gunderson L, Tepper J, editors. *Clinical Radiation Oncology*. 3rd edition. Philadelphia, PA: Churchill Livingstone; 2012:1400.
20. Strom T, Caudell JJ, Han D, et al. Radiotherapy influences local control in patients with desmoplastic melanoma. 2014;120(9):1369-1378.